Lupin has experienced an information security incident that has affected its select internal IT systems. 

 

According to the company, the incident is currently not material and has not impacted its core systems and operations. The restoration of the impacted systems is a priority and is underway.

 

Lupin is a global pharmaceutical company offering a wide range of products such as Branded & Generic Formulations, Biotechnology Products, Active Pharmaceutical Ingredients (APIs) and Specialty. 

 

Lupin is a significant player in the therapy areas of Gynaecology, Cardiovascular, Diabetology, Asthma, Paediatric, Central Nervous System (CNS), Gastro Intestinal (GI), Anti-Infective (AI) and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Lupin also holds a global leadership position in the Anti-TB and Cephalosporins segments. 

 

With a presence in over 100 countries, Lupin offers high-quality yet affordable medicines for some of the most chronic diseases addressing unmet needs in many parts of the world.